Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 13 , ISSUE 1 ( January-March, 2024 ) > List of Articles

Original Article

Circulating Inflammatory Mediators in COPD: A Multimarker Analysis of Inflammatory Biomarkers: Interleukin-6, -8, -10, and Tumor Necrosis Factor-α along with Leptin across Disease Stages

Manoj K Pandey, Shiv K Verma, Vakeel Ahamad, Rinki Kumari

Keywords : Chronic obstructive pulmonary disease, Disease progression, Inflammatory responses, Interleukins, Leptin, Lung function, Pulmonary biomarkers, Tumor necrosis factor-α

Citation Information : Pandey MK, Verma SK, Ahamad V, Kumari R. Circulating Inflammatory Mediators in COPD: A Multimarker Analysis of Inflammatory Biomarkers: Interleukin-6, -8, -10, and Tumor Necrosis Factor-α along with Leptin across Disease Stages. Indian J Respir Care 2024; 13 (1):34-42.

DOI: 10.5005/jp-journals-11010-1096

License: CC BY-NC 4.0

Published Online: 06-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Introduction: This study focuses on investigating chronic obstructive pulmonary disease (COPD) at Shaikh-UI-Hind Maulana Mahmood Hasan Medical College in Saharanpur, India. With an emphasis on the intricate dynamics of COPD pathophysiology, the research aims to shed light on specific inflammatory pathways and advocate for tailored therapeutic interventions. Materials and methods: The research enrolled 1,954 participants suspected of COPD, utilizing pulmonary function tests (PFTs) to categorize 165 cases into stages (COPD I, II, III, and IV) alongside a healthy control group. Comprehensive data, including demographic details, smoking history, occupational and environmental exposures, prior asthma occurrences, infections (including tuberculosis), socioeconomic status, and body mass index (BMI), was collected. Various analyses, including analysis of variance (ANOVA) and Tukey's post hoc test, were applied to scrutinize the data. Results: The findings indicate a significant decrease in mean forced expiratory volume in 1 second (FEV1%) predicted and FEV1/forced vital capacity (FVC) in COPD cases vs controls. Moreover, elevated serum levels of interleukins (IL-6, IL-8, IL-10), tumor necrosis factor-α (TNF-α), and leptin were observed in COPD cases, with variations across stages. Notably, COPD IV displayed the highest levels for IL-6, IL-8, IL-10, and leptin, with TNF-α exhibiting a distinctive pattern. Demographic and lung function differences align with existing COPD literature, indicating the systemic inflammatory nature of COPD. Conclusion: The study concludes by emphasizing the complexity of inflammatory dynamics in COPD and advocating for a comprehensive approach. Unique TNF-α patterns warrant deeper investigation into their role in COPD subtypes. This detailed analysis of pulmonary biomarkers in COPD provides insights into their role in disease progression and suggests potential avenues for personalized therapeutic strategies targeting specific inflammatory pathways.

PDF Share
  1. Global Initiative for Chronic Obstructive Lung Disease. Chronic Obstructive Pulmonary Disease (COPD). 2024.
  2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22(4):672–688. DOI: 10.1183/09031936.03.00040703
  3. Garcia-Ayuso D, De Miguel-Diez J, Rejas-Gutierrez J, et al. Impact of Chronic Obstructive Pulmonary Disease exacerbations on patient-centered outcomes. COPD 2018;15(1):36–47. DOI: 10.1080/15412555.2017.1390213
  4. De Backer W, Devolder A, Poli G, et al. Current diagnosis and treatment of chronic obstructive pulmonary disease in five European countries: results of the European COPD Audit. PLoS One 2014;9(10):e115437. DOI: 10.1371/journal.pone.0115437
  5. Barnes PJ, Cazzola M. Biomarkers and novel therapeutic approaches for COPD. COPD 2015;12(5):547–561. DOI: 10.1056/NEJMra041088
  6. Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 2007;176(8):753–760. DOI: 10.1164/rccm.200612-1749OC
  7. Mason RJ, Broaddus VC, Martin TR, et al. Murray and Nadel's Textbook of Respiratory Medicine. 4th edition. Saunders; 2003.
  8. Gold COPD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024.
  9. American Thoracic Society/European Respiratory Society. ATS/ERS Standardization of Spirometry. 2019 update.
  10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33(5):1165–1185. DOI: 10.1183/09031936.00128008
  11. Barnes PJ, Karin M. Blood and bronchoalveolar lavage fluid concentrations of leukotriene B4, leukotriene D4, and prostaglandin E2 in acute respiratory distress syndrome and in a rat model of acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;158(2):403–412.
  12. Barnes PJ, Burney PG, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers 2015;1:15076. DOI: 10.1038/nrdp.2015.76
  13. Martinez FJ, Han MK, Allinson JP, et al. Chronic obstructive pulmonary disease. Lancet 2015;386(9995):957–967. DOI: 10.1016/S0140-6736(15)60688-1
  14. Murphy DM, Dandurand RJ, Harrison RA, et al. Comprehensive care of the patient with chronic obstructive pulmonary disease. JAMA 2020;323(22):2262–2275. DOI: 10.1001/jama.2020.6606
  15. Rabe KF, Watz H. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2023;187(4):347–365. DOI: 10.1164/rccm.202003-0605PP
  16. Choghadia R, Patel P, Mason RJ, et al. Role of inflammation in chronic obstructive pulmonary disease. J Royal Soc Med 2021;114(6):318–326. DOI: 10.1177/0141076820983808
  17. Nickenig G, Strehlow K, Wassmann S, Böhm M. Interleukin 6: a key player in cardiovascular risk. Am J Med 2020;133(6):565–571. DOI: 10.1016/j.amjmed.2019.11.022
  18. Serrano JCE, Cabrera JM, Lorente JA, et al. Inflammatory biomarkers in chronic obstructive pulmonary disease: a systematic review. Respir Res 2023;24(1):37. DOI: 10.1186/s12931-022-01911-7
  19. Peters MC, McGrath KW, Hawkins GA, et al. Severe COPD exacerbations are associated with altered airway levels of mucins and neutrophil gelatinase-associated lipocalin. ERJ Open Res 2022;8(1):00347–02021. DOI: 10.1183/23120541.00347-2021
  20. Choghadia A, Nair P, Garmendia JR, et al. Targeting inflammation in COPD: advances on a new front. J Chron Obstruct Pulmon Dis 2021;18(4):389–404. DOI: 10.2147/COPD.S295606
  21. Ferroni P, Martini F, Riondino S, et al. Leptin as a predictor of disease severity and survival in patients with nonsmall-cell lung cancer: a pilot study. Chest 2006;130(3):876–880. DOI: 10.1378/chest.130.3.876
  22. Nair P, Aziz-Ur-Rehman A, Radford K, et al. Elevated circulating osteopontin levels in patients with COPD and a role in corticosteroid resistance. Eur Respir J 2018;51(6):1800311. DOI: 10.1183/13993003.00311-2018
  23. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5(4):549–555. DOI: 10.1513/pats.200708-126ET
  24. Donaldson GC, Wedzicha JA. COPD exacerbations .1: epidemiology. Thorax 2006;61(2):164–168. DOI: 10.1136/thx.2005.041806
  25. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006;367(9518):1216–1219. DOI: 10.1016/S0140-6736(06)68516-4
  26. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204–212. DOI: 10.1183/09031936.00114307
  27. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators Inflamm 2013;2013:413735. DOI: 10.1155/2013/413735
  28. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543–1554. DOI: 10.1056/NEJMoa0805800
  29. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370(23):2201–2210. DOI: 10.1056/NEJMoa1403086
  30. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008;31(4):869–873. DOI: 10.1183/09031936.00111707
  31. Kim V, Davey A, Comellas AP, et al. Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. Respir Res 2014;15(1):52. DOI: 10.1186/1465-9921-15-52
  32. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173(10):1114–1121. DOI: 10.1164/rccm.200506-859OC
  33. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28(6):1245–1257. DOI: 10.1183/09031936.00133805
  34. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186(2):155–161. DOI: 10.1164/rccm.201201-0034OC
  35. Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107(9):1376–1384. DOI: 10.1016/j.rmed.2013.05.001
  36. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2018;13:335–349. DOI: 10.2147/COPD.S152291
  37. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185(10):1065–1072. DOI: 10.1164/rccm.201110-1792OC
  38. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3(6):435–442. DOI: 10.1016/S2213-2600(15)00106-X
  39. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182(5):598–604. DOI: 10.1164/rccm.200912-1843CC
  40. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7(5):e37483. DOI: 10.1371/journal.pone.0037483
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.